|
" Silymarin for the Prevention of Contrast-Induced Nephropathy: A Placebo-Controlled Clinical Trial "
/ Zohreh Sedighifard
; Farshad Roghani
| center
|
:
|
Isfahan University of Medical Sciences
|
| Document Type
|
:
|
Latin Dissertation
|
| Language of Document
|
:
|
English
|
| Record Number
|
:
|
106133
|
| Doc. No
|
:
|
T16448
|
| Call number
|
:
|
WJ342,S448s,2015
|
| Main Entry
|
:
|
Sedighifard, Zohreh
|
| Title & Author
|
:
|
Silymarin for the Prevention of Contrast-Induced Nephropathy: A Placebo-Controlled Clinical Trial/ Zohreh Sedighifard
|
| College
|
:
|
Schools, Medical
|
| Date
|
:
|
, 2015
|
| Degree
|
:
|
Cardiology, Speciality
|
| Page No
|
:
|
19p.: diag, tab
|
| Note
|
:
|
This is a research dissertation with project ID: 393752
|
|
|
:
|
زهره صدیقی فرد
|
| Abstract
|
:
|
Background: Silymarin is a flavonoid complex with nephro-protective properties. We evaluated the efficacy of silymarin in the prevention of contrast-induced nephropathy (CIN).Methods: This placebo-controlled clinical trial was conducted on 143 patients with chronic stable angina referring for elective coronary angiography. Patients with low to moderate risk for CIN were included and were randomized to receive silymarin (280 mg) or placebo 2 hours before administration of the contrast material. A non-ionic, iso-osmolar contrast material was used. Serum creatinine was measured before and 48 hours after contrast material injection. CIN was defined as an increase in creatinine of ≥0.5 mg/dL or ≥25% from the baseline.Results: Serum creatinine was increased by 0.02±0.07 mg/dL (P = 0.004) with silymarin and by 0.04±0.15 mg/dL (P = 0.008) with placebo after contrast material injection (between group difference = 0.01±0.02 mg/dL, P = 0.881). CIN was occurred less frequently, though statistically non-significant, with silymarin compared with placebo (2.9% vs. 10.8%, OR [95% CI] = 0.246 [0.050 to 1.203], P = 0.099). In the logistic regression analysis controlling for patients characteristics and baseline creatinine level, silymarin was non-significantly associated with lower frequency of CIN (OR [95% CI] = 0.203 [0.037 to 1.117], P = 0.067).Conclusion: We found a trend toward the efficacy of silymarin in preventing contrast-induced renal dysfunction. Further trials with larger sample size and in patients with higher risk of CIN are warranted.
|
| Descriptor
|
:
|
Acute Kidney Injury
|
|
|
:
|
Contrast Media
|
|
|
:
|
Silymarin
|
|
|
:
|
Plants, Medicinal
|
|
|
:
|
Biflavonoids
|
| Added Entry
|
:
|
Roghani, Farshad, Thesis advisor
|
| Translated Title Supplied by Cataloguer
|
:
|
سیلیمارین برای پیشگیری از نفروپاتی ناشی از کنتراست
|
| |